ASX · NEU.AX
Neuren Pharmaceuticals Limited
A$20.44+A$0.30 (+1.49%)
Neuren Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 14.02% below the high.
Loading market information…
ASX · NYR.AX · AUD
Stock price, earnings
Quote as of Oct 30, 2026, 04:49 AM UTC. Cached market data; not a live quote.
One-year closing-price history · AUD. Historical prices are not a forecast.
Nyrada Inc.’s quoted price sits in the lower half of its reported 52-week range, 67.71% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nyrada Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nyrada Inc., a pre-clinical stage drug development company, engages in the development of small molecule drugs for cardiovascular and neurological diseases. Its lead candidate is Xolatryp, a small molecule drug which has completed phase 1 clinical trial for neuroprotection and cardioprotection indications and in patients with traumatic brain injury and ischaemic stroke. Nyrada Inc. was incorporated in 2017 and is based in Sydney, Australia.
Latest available per-share figures in AUD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 05:11 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
A$20.44+A$0.30 (+1.49%)
Neuren Pharmaceuticals Limited’s quoted price sits in the upper half of its reported 52-week range, 14.02% below the high.
A$0.04-A$0.00 (-4.65%)
Actinogen Medical Limited’s quoted price sits in the lower half of its reported 52-week range, 43.06% below the high.
A$0.09A$0.00 (0.0%)
Neurizon Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 31.2% below the high.
A$0.05+A$0.00 (+3.92%)
Arovella Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 47.0% below the high.
A$0.26-A$0.00 (0.0%)
Alterity Therapeutics Limited’s quoted price sits in the lower half of its reported 52-week range, 66.88% below the high.
A$0.02+A$0.00 (+5.88%)
Neurotech International Limited’s quoted price sits in the upper half of its reported 52-week range, 14.29% below the high.
A$0.05A$0.00 (0.0%)
NeuroScientific Biopharmaceuticals Limited’s quoted price sits in the lower half of its reported 52-week range, 70.0% below the high.
A$0.12+A$0.01 (+9.52%)
Argenica Therapeutics Ltd’s quoted price sits in the lower half of its reported 52-week range, 66.67% below the high.
